Related Experiment Video
Updated: Jul 12, 2025

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab
Ysoline Beigneux1, Celine Louapre1, Kevin Bihan2
1Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France.
Background:
Late-onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1500/mm3 that develops between 4 weeks and 6 months after the last drug administration, is a rare side effect of anti-CD20 drugs including ocrelizumab. Although continuation of ocrelizumab after LON is not contraindicated, the risk of LON recurrence is not well known.
Cases:
We report three cases of recurrent symptomatic agranulocytosis (ANC < 500/mm3) occurring under ocrelizumab.
Conclusion:
Given the risk of recurrence of symptomatic agranulocytosis and the availability of other treatments, a therapeutic switch may be discussed after the first episode of LON.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations

